1
|
Delibes C, Ferré M, Rozet M, Desquiret-Dumas V, Descatha A, Gohier B, Gohier P, Amati-Bonneau P, Milea D, Reynier P. Genetic susceptibility to optic neuropathy in patients with alcohol use disorder. J Transl Med 2024; 22:495. [PMID: 38796496 PMCID: PMC11127293 DOI: 10.1186/s12967-024-05334-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2024] [Accepted: 05/20/2024] [Indexed: 05/28/2024] Open
Abstract
BACKGROUND The pathophysiology of toxico-nutritional optic neuropathies remains debated, with no clear understanding of the respective roles played by the direct alcohol toxicity, smoking and the often associated vitamin deficiencies, which are risk factors for optic neuropathy. Our aim was to investigate genetic susceptibility in patients with bilateral infraclinical optic neuropathy associated with chronic alcohol use disorder. METHODS This retrospective cohort study included 102 visually asymptomatic patients with documented alcohol use disorder from a French reference center. Optic neuropathy was identified with optical coherence tomography (OCT), after which genetic susceptibility in the group of affected patients was investigated. Genetic testing was performed using panel sequencing of 87 nuclear genes and complete mitochondrial DNA sequencing. RESULTS Optic neuropathy was detected in 36% (37/102) of the included patients. Genetic testing of affected patients disclosed two patients (2/30, 6.7%) with optic neuropathy associated with pathogenic variants affecting the SPG7 gene and five patients (5/30, 16.7%) who harbored variants of uncertain significance close to probable pathogenicity in the genes WFS1, LOXL1, MMP19, NR2F1 and PMPCA. No pathogenic mitochondrial DNA variants were found in this group. CONCLUSIONS OCT can detect presence of asymptomatic optic neuropathy in patients with chronic alcohol use disorder. Furthermore, genetic susceptibility to optic neuropathy in this setting is found in almost a quarter of affected patients. Further studies may clarify the role of preventative measures in patients who might be predisposed to avoidable visual loss and blindness.
Collapse
Affiliation(s)
- Camille Delibes
- Département d'Ophtalmologie, Centre Hospitalier Universitaire (CHU), 49000, Angers, France
| | - Marc Ferré
- Université d'Angers, Unité Mixte de Recherche (UMR) MITOVASC, Institut National de la Santé et de la Recherche Médicale (INSERM U-1083), Centre National de la Recherche Scientifique (CNRS 6015), 49000, Angers, France
- Département de Biochimie et Biologie Moléculaire, Centre Hospitalier Universitaire, 49000, Angers, France
| | - Marine Rozet
- Département de Psychiatrie et d'Addictologie, Centre Hospitalier Universitaire, 49000, Angers, France
| | - Valérie Desquiret-Dumas
- Université d'Angers, Unité Mixte de Recherche (UMR) MITOVASC, Institut National de la Santé et de la Recherche Médicale (INSERM U-1083), Centre National de la Recherche Scientifique (CNRS 6015), 49000, Angers, France
- Département de Biochimie et Biologie Moléculaire, Centre Hospitalier Universitaire, 49000, Angers, France
| | - Alexis Descatha
- Univ. Angers (University of Angers), CHU Angers, Univ. Rennes, Inserm, EHESP, IRSET (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, IRSET-ESTER, SFR ICAT, CAPTV CDC, 49000, Angers, France
- Department of Occupational Medicine, Epidemiology and Prevention, Donald and Barbara Zucker School of Medicine, Hosftra University Northwell Health, New York, NY, 11021, USA
| | - Bénédicte Gohier
- Département de Psychiatrie et d'Addictologie, Centre Hospitalier Universitaire, 49000, Angers, France
- Univ Angers, Université de Nantes, LPPL, SFR CONFLUENCES, 49000, Angers, France
| | - Philippe Gohier
- Département d'Ophtalmologie, Centre Hospitalier Universitaire (CHU), 49000, Angers, France
| | - Patrizia Amati-Bonneau
- Université d'Angers, Unité Mixte de Recherche (UMR) MITOVASC, Institut National de la Santé et de la Recherche Médicale (INSERM U-1083), Centre National de la Recherche Scientifique (CNRS 6015), 49000, Angers, France
- Département de Biochimie et Biologie Moléculaire, Centre Hospitalier Universitaire, 49000, Angers, France
| | - Dan Milea
- Département d'Ophtalmologie, Centre Hospitalier Universitaire (CHU), 49000, Angers, France
- Singapore National Eye Centre, Singapore Eye Research Institute, Duke-NUS, Singapore, Singapore
- Rothschild Foundation Hospital, Paris, France
| | - Pascal Reynier
- Université d'Angers, Unité Mixte de Recherche (UMR) MITOVASC, Institut National de la Santé et de la Recherche Médicale (INSERM U-1083), Centre National de la Recherche Scientifique (CNRS 6015), 49000, Angers, France.
- Département de Biochimie et Biologie Moléculaire, Centre Hospitalier Universitaire, 49000, Angers, France.
| |
Collapse
|
2
|
Use of Visual Electrophysiology to Monitor Retinal and Optic Nerve Toxicity of Medications. Biomolecules 2022; 12:biom12101390. [PMID: 36291599 PMCID: PMC9599231 DOI: 10.3390/biom12101390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2022] [Revised: 09/26/2022] [Accepted: 09/26/2022] [Indexed: 12/03/2022] Open
Abstract
It is important for clinicians to consider exposure to toxic substances and nutritional deficiencies when diagnosing and managing cases of vision loss. In these cases, physiologic damage can alter the function of key components of the visual pathway before morphologic changes can be detected by traditional imaging methods. Electrophysiologic tests can aid in the early detection of such functional changes to visual pathway components, including the retina or optic nerve. This review provides an overview of various electrophysiologic techniques, including multifocal electroretinogram (mfERG), full-field ERG (ffERG), electrooculogram (EOG), pattern electroretinogram (PERG), and visual evoked potential (VEP) in monitoring the retinal and optic nerve toxicities of alcohol, amiodarone, cefuroxime, cisplatin, deferoxamine, digoxin, ethambutol, hydroxychloroquine, isotretinoin, ocular siderosis, pentosane, PDE5 inhibitors, phenothiazines (chlorpromazine and thioridazine), quinine, tamoxifen, topiramate, vigabatrin, and vitamin A deficiency.
Collapse
|